Effects of oral anti-diabetic agent sitagliptin on total antioxidant and oxidant status in rats with type 2 diabetes mellitus

Journal of Applied Biological Sciences

Volumn 8, Issue 1, 2014, Pages 31-37

  Hazman, Ömer ^a   Çelik, Sefa ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

OSI; Oxidative stress; Sitagliptin; TAS; TOS; Type 2 diabetes

Indexed keywords

EID: 84903448009     PISSN: 13071130     EISSN: 21460108     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Deacon CF. 2007. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs. 16: 533-545.
2. Ahren B. 2007. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 21(4): 517-533.
3. Miller SA, Onge EL. 2006. Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. Ann Pharmacother. 40:1336-43.
4. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, et al. 2005. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clin Pharmacol. Ther. 78(6): 675-88.
5. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, et al. 2006. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Mono-therapy on Glycemic Control in Patients with Type 2 Diabetes. Diabetes Care. 29: 2632-2637.
6. Raz I, Hanefeld M, Xu L, Caria C. 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as mono-therapy in patients with type 2 diabetes mellitus. Diabetologia. 49: 2564-2571
7. Rosenstock J, Brazg R, Andryuk P.J. 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicentre, randomised, double-blind, placebo-controlled, parallel-group study. Clin Ther. 28(10): 1556-1568.
8. Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, et al. 2009. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 25(3): 569-83.
9. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, et al. 2005. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 48: 1168-1172.
10. Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, et al. 2006. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol. 155: 485-493.
11. Vilsboll T, Krarup T, Deacon C, Madsbad S, Holst JJ. 2001. Reduced postprandial concentrations of intact biologically active glucagons-like peptide 1 in type 2 diabetic patients. Diabetes. 50: 609-13.
12. McKennon SA, Campbell RK. 2007. The Physiology of Incretin Hormones and the Basis for DPP-4 Inhibitors. Diabetes Educator. 33: 55-66.
13. Atamer Y, Koçyiǧit Y, Atamer A, Mete N, Canoruç N, et al. 1998. Alterations of Erythrocyte and Plasma Lipid Peroxides as well as Antioxidant Mechanism in Patients with Type II Diabetes Mellitus (NIDDM). Turk J Med Sci. 28: 143-148.
14. Memişoǧullari R, Türkeli M, Bakan E, Akçay F. 2008. Effect of Metformin or Gliclazide on Lipid Peroxidation and Antioxidant Levels in Patients with Diabetes Mellitus. Turk J Med Sci. 38(6): 545-548.
15. Zhang M, Lv MY, Li J, Xu ZG, Chen L. 2008. The Characterization of High-Fat Diet and Multiple Low-Dose Streptozotocin Induced Type 2 Diabetes Rat Model. Exp Diabetes Res. Article ID 704045, 1-9.
16. D'amico M, Filippo CD, Marfella R, Abbatecola A. M, Ferraraccio F, et al. 2010. Long-term inhibition of dipeptidyl peptidase-4 Alzheimer's prone mice. Exp Gerontol. 45: 202-207.
17. Erel O. 2004. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 37(4): 277-85.
18. Erel O. 2005. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 38(12):1103-11.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. 1985. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419
20. Durham HA, Truett GE. 2006. Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol. 290(3): 652-658.
21. Robertson RP, Harmon J, Tran PO, Poitout V. 2004. β-cell glucose toxicity, lipotoxicity, and chronic oxidative street inn type 2 diabetes. Diabetes. 53(Supplement 1), 119-124.
22. Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, et al. 2005. The effects of Rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 20(12): 3333-3340.
23. Maritim AC, Sanders RA, Watkins JB. 2003. Diabetes, oxidative stress and antioxidants: a review. J Biochem MolToxicol. 17(1): 24-38.
24. Ceriello A. 2003. New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy. Diabetes Care. 26: 1589-1596.
25. Abou-Seif MA, Youssef AA. 2004. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta. 346: 161-170.
26. Whiting PH, Kalansooriya A, Holbrook I, Haddad F, Jennings PE. 2008. The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. Br J Biomed Sci. 65(2): 71-4.
27. Koksal M, Eren MA, Turan MN, Sabuncu T. 2011. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. Eur J of Intern Med. 22(3): 249-253.
28. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, et al. 2010. Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat). Mediators Inflamm. doi:10.1155/2010/592760, In press.
29. Altan N, Dincel AS, Koca C. 2006. Diabetes Mellitus and Oxidative Stress. Turk J Biochem, 31 (2); 51-56.
30. Poucher SM, Cheetham S, Francis J, Zinker B, Kirby M, et al. 2012. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes Obes Metab; doi: 10.1111/j.1463-1326.2012.01619.x.,In press.
31. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, et al. 2011. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat), Exp Diabetes Res; doi: 10.1155/2011/162092, In press.